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IMPORTANCE—Pancreatic mucinous cystic neoplasms (MCNs) harbor malignant potential, and 
current guidelines recommend resection. However, data are limited on preoperative risk factors for 
malignancy (adenocarcinoma or high-grade dysplasia) occurring in the setting of an MCN.
OBJECTIVES—To examine the preoperative risk factors for malignancy in resected MCNs and 
to assess outcomes of MCN-associated adenocarcinoma.
DESIGN, SETTING, AND PARTICIPANTS—Patients who underwent pancreatic resection of 
MCNs at the 8 academic centers of the Central Pancreas Consortium from January 1, 2000, 
through December 31, 2014, were retrospectively identified. Preoperative factors of patients with 
and without malignant tumors were compared. Survival analyses were conducted for patients with 
adenocarcinoma.
MAIN OUTCOMES AND MEASURES—Binary logistic regression models were used to 
determine the association of preoperative factors with the presence of MCN-associated 
malignancy.
RESULTS—A total of 1667 patients underwent resection of pancreatic cystic lesions, and 349 
(20.9%) had an MCN (310 women [88.8%]; mean (SD) age, 53.3 [14.7] years). Male sex (odds 
ratio [OR], 3.72; 95% CI, 1.21–11.44; P = .02), pancreatic head and neck location (OR, 3.93; 95% 
CI, 1.43–10.81; P = .01), increased radiographic size of the MCN (OR, 1.17; 95% CI, 1.08–1.27; 
P < .001), presence of a solid component or mural nodule (OR, 4.54; 95% CI, 1.95–10.57; P < .
001), and duct dilation (OR, 4.17; 95% CI, 1.63–10.64; P = .003) were independently associated 
with malignancy. Malignancy was not associated with presence of radiographic septations or 
preoperative cyst fluid analysis (carcinoembryonic antigen, amylase, or mucin presence). The 
median serum CA19-9 level for patients with malignant neoplasms was 210 vs 15 U/mL for those 
without (P = .001). In the 44 patients with adenocarcinoma, 41 (93.2%) had lymph nodes 
harvested, with nodal metastases in only 14 (34.1%). Median follow-up for patients with 
adenocarcinoma was 27 months. Adenocarcinoma recurred in 11 patients (25%), with a 64% 
recurrence-free survival and 59% overall survival at 3 years.
CONCLUSIONS AND RELEVANCE—Adenocarcinoma or high-grade dysplasia is present in 
14.9% of resected pancreatic MCNs for which risks include male sex, pancreatic head and neck 
location, larger MCN, solid component or mural nodule, and duct dilation. Mucinous cystic 
neoplasm-associated adenocarcinoma appears to have decreased nodal involvement at the time of 
resection and increased survival compared with typical pancreatic ductal adenocarcinoma. 
Indications for resection of MCNs should be revisited.
Mucinous cystic neoplasms (MCNs) of the pancreas are rare cysts with malignant potential 
that typically occur in the pancreatic body or tail of perimenopausal women.1 Mucinous 
cysts were first distinguished from the typically benign serous cysts by Compagno and 
Oertel2,3 in the 1970s. Later, in 2000, the World Health Organization (WHO) proposed 
criteria that further defined MCNs by their ovarian stroma on histologic analysis; these 
diagnostic criteria better distinguish MCNs from premalignant mucinous pancreatic ductal 
cysts of intraductal papillary mucinous neoplasms (IPMNs).4,5 The risk of high-grade 
dysplasia (HGD) or invasive adenocarcinoma within an MCN has varied in the literature 
from 10% to 39%.6–11
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Given the possibility of malignant transformation, resection is a consideration for 
management of IPMNs and MCNs. Recent international consensus guidelines have 
proposed that branch-duct IPMNs with concerning features (symptoms, ductal dilatation, 
presence of mural nodule, and size >3 cm) should be managed operatively in appropriate 
patients; however, for IPMNs that lack any of these features, radiographic surveillance may 
be appropriate.12,13 These resection guidelines for IPMNs have been found to be sensitive 
but not specific for malignancy.14 For the management of MCNs, however, these same 
consensus guidelines recommend resection of all MCNs in patients who are operative 
candidates.12,13
Despite these aggressive recommendations, the risk factors for developing malignant MCNs 
are not well characterized.13,15 The literature that addresses factors associated with 
malignant MCNs is limited by single-institution series and small sample sizes and has 
primarily focused on pathologic factors that are determined postoperatively rather than on 
preoperative factors that could potentially optimize management strategy.6–9,11,15–21 We 
sought to determine preoperative factors associated with increased risk of malignancy in 
patients with resected MCNs in a modern US cohort of patients undergoing resection of 
MCNs at 8 institutions after the 2000 WHO diagnostic guidelines were in place.4
Methods
Patient Population
The Central Pancreas Consortium represents a collaboration of 8 academic medical centers 
in the United States: Winship Cancer Institute of Emory University, Atlanta, Georgia; 
Vanderbilt University Medical Center, Nashville, Tennessee; Washington University School 
of Medicine, St Louis, Missouri; University of Wisconsin School of Medicine and Public 
Health, Madison; University of Louisville, Louisville, Kentucky; Northwestern University 
Feinberg School of Medicine, Chicago, Illinois; University of North Carolina at Chapel Hill; 
and University of Cincinnati Cancer Institute, Cincinnati, Ohio. All patients who underwent 
resection of pancreatic cystic lesions from January 1, 2000, to December 31, 2014, were 
identified. Patients with a pathologic diagnosis of pancreatic MCNs were included. 
Clinicopathologic, treatment, recurrence, and outcome data were collected through 
retrospective medical record review. Survival data were primarily gathered from documented 
clinical follow-up and were confirmed using the Social Security Death Index database. This 
study was approved by the institutional review boards of all participating centers, and ethical 
standards of the committees on human experimentation of these institutions were maintained 
and consent waived.
Statistical Analysis
Comparisons of categorical variables were conducted with χ2 or Fisher exact tests. Two-
tailed t tests were used to compare parametric data, whereas Mann-Whitney tests were used 
for assessment of nonparametric data. Associations between preoperative factors and 
adenocarcinoma or HGD were determined with univariate binary logistic regression 
analysis. Variables with a statistically significant association on univariate analyses were 
included in a multivariable binary logistic regression model. Survival was estimated by 
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Kaplan-Meier log-rank analyses; 90-day postoperative mortalities were excluded from 
recurrence and survival analyses. Statistical analyses were conducted using SPSS statistical 
software, version 23.0 (IBM). P < .05 was considered statistically significant.
Results
Patient Population and Risk of Adenocarcinoma or HGD
A total of 1667 patients underwent resection of pancreatic cystic lesions, and 349 (20.9%) 
had an MCN (310 women [88.8%]; mean (SD) age, 53.3 [14.7] years). All MCNs were 
solitary lesions, with most occurring in the distal pancreas (294 [84.2%]). Most patients 
were symptomatic at presentation (223 [63.9%]), with symptoms of abdominal pain or 
discomfort, abdominal fullness, pancreatitis, and jaundice. The mean (SD) radiographic size 
of the resected MCNs was 5 (4.1) cm, with a solid component or mural nodule in 71 of 289 
MCNs (24.6%) and pancreatic duct dilation present in 50 of 293 patients (17.1%). Further 
data on presentation, clinicopathologic factors, and treatment of all patients undergoing 
MCN resection are described in Table 1.
Fifty-two MCNs (14.9%) had associated adenocarcinoma (44 [12.6%]) or HGD (8 [2.3%]). 
Male sex (15 [28.8%] vs 24 [8.1%]; P < .001), pancreatic head and neck location (19 
[38.8%] vs 36[12.5%]; P < .001), increased radiographic size of the MCN (7.2 vs 4.6 cm; P 
= .004), radiographic presence of a solid component or mural nodule (22 [53.7%] vs 49 
[19.8%]; P < .001), and duct dilation (19 [43.2%] vs 31 [12.4%]; P < .001) were associated 
with adenocarcinoma or HGD compared with benign MCNs. Adenocarcinoma or HGD was 
not associated with the presence of radiographic septations or preoperative cyst fluid 
analysis (carcinoembryonic antigen, amylase, or mucin presence). The median serum 
CA19-9 level for patients with adenocarcinoma or HGD was 210 U/mL (range, 2–546 470 
U/mL) (n = 102) compared with 15 U/mL (range, 1–10 529 U/mL) (n = 29) for those 
without (P = .001). These differences between patients with and without adenocarcinoma or 
HGD are further outlined in Table 1.
On univariate binary logistic regression, neither cyst fluid analysis nor serum CA19-9 was 
predictive of malignancy (Table 2). However, male sex, increased radiographic size of the 
MCN, pancreatic head and neck location, presence of a solid component or mural nodule, 
and duct dilation were associated with adenocarcinoma or HDG on final pathologic analysis 
(Table 2). When accounting for these factors in multivariable analysis, all persisted as 
independent preoperative risk factors for adenocarcinoma or HGD (Table 2). Ten patients 
with adenocarcinoma or HGD had MCNs smaller than 3 cm. For these patients with small 
malignant lesions, 6 (60%) had at least 2 other high-risk features: male sex, pancreatic head 
and neck location, solid component, or dilated duct.
MCN-Associated Adenocarcinoma, Recurrence, and Survival
In the 44 patients with adenocarcinoma, 41 (93.2%) had lymph nodes harvested, with nodal 
metastases in only 14 patients (34.1%). One patient with adenocarcinoma died within 90 
days of surgery. These patients are further described in Table 3. The median follow-up for 
patients with adenocarcinoma was 27 months (range, 0.21–143.1 months). The 3-year 
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recurrence-free survival was 64% (Figure 1), and overall survival for patients with MCN-
associated adenocarcinoma was 59% at 3 years (Figure 2). For patients who did not have 
invasive MCNs, there were no events of recurrence.
Discussion
To our knowledge, this study represents the largest series in the literature describing 
preoperative factors associated with malignancy in patients undergoing resection of MCNs. 
In 349 patients, 52 (14.9%) had MCN-associated adenocarcinoma or HGD. Male sex, 
pancreatic head and neck location, increased radiographic size of the MCN, presence of a 
solid component or mural nodule, and pancreatic duct dilation on preoperative imaging were 
independently associated with adenocarcinoma or HGD. For the 44 patients with invasive 
adenocarcinoma, the 3-year recurrence-free and overall survival rates were 64% and 59%, 
respectively, whereas there were no recurrences in patients with noninvasive MCN.
With increased use and advancements in cross-sectional imaging, the diagnosis of MCNs 
has been increasing over time.22 In a 15-year series of resections of pancreatic cystic lesions, 
MCNs constituted 21% of all pathologic findings. Similarly, in other series that span 
decades, 10% to 45% of resected pancreatic cystic lesions were MCNs.23,24 Unlike the more 
common cystic lesion IPMNs, for which consensus guidelines offer clear criteria for 
surveillance or resection, resection is recommended in all patients with MCNs who are 
deemed surgical candidates.12,13 However, there are limited data to support these aggressive 
recommendations for MCNs, and understanding the preoperative risk of MCN-associated 
malignancy becomes integral in determining appropriate treatment strategies. In addition, as 
diagnoses of MCN become more frequent, defining criteria for resection to better balance 
operative morbidity with potential benefit in a larger population becomes even more 
essential.
Despite its increasing importance, the natural history of MCNs is not well understood. 
Although some have argued that all MCNs represent premalignant entities,13,15 others have 
contended that some MCNs may be indolent and do not pose that risk.25 Until now, 
studies6–9,11,15–21 that have attempted to elucidate the risks of malignancy in resected MCNs 
have been limited by small sample sizes, which may not be representative of MCNs as a 
whole and did not allow for creation of multivariable models, exhibited single institutional 
bias, or focused on postoperative pathologic predictors rather than factors that can be 
assessed before surgical intervention. To circumvent these issues, the current study included 
a large population from 8 centers across the United States with a goal of determining 
preoperative rather than pathologic factors associated with malignancy that could be applied 
to treatment algorithms before resection.
Malignancy in MCNs is neither uncommon nor pervasive. Series of resected MCNs during 
the past few decades have reported adenocarcinoma or HGD in 10% to 39% of surgical 
specimens; similarly, the rate of adenocarcinoma or HGD in this modern Western series was 
15%.6,7,9–11,18–21,23 When studies6,8,9,11,18–21 have distinguished between invasive disease 
and carcinoma in situ, invasive adenocarcinoma rates ranged from 1% to 16%, which is 
comparable to the 13% reported in this series. In addition, although other series have 
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reported HGD in 4% to 12% of MCNs, the rate was lower in the current series 
(2%).6,9,11,18–21
Although MCNs are more common in females because the presence of ovarian stroma 
represents one of the diagnostic criteria per the WHO 2000 definition,4 this pathologic entity 
also occurs in men.6,15,18–21 In the present study, 11% of patients with MCNs were male, 
and male sex was associated with increased risk of malignancy. When 
studies6,9,16,18,20,21,23,26 have included only patients with MCNs defined by their ovarian 
stroma, the occurrence of MCNs in men has been reported at frequencies between 0% and 
20%. In previous studies,6,15,18–21 adenocarcinoma or HGD has been common in males with 
MCNs; however, the present study is the first, to our knowledge, to identify an independent 
association between male sex and increased risk of malignancy in MCNs.
In addition to patient demographics, preoperative laboratory values could help to predict 
malignancy risk. Few other series have evaluated the preoperative CA19-9 value and risk of 
malignancy within an MCN.6,11 Like these previous studies,6,11 the present study found that 
an elevated CA19-9 level was associated with increased risk of malignancy; however, this 
association did not persist in multivariable analysis. Analyses of MCN cyst fluid for 
carcinoembryonic antigen, amylase, and presence of mucin have also been investigated. 
When evaluating pancreatic cysts, carcinoembryonic antigen cystic fluid levels can help 
predict whether a cyst is mucinous (MCN or IPMN); however, beyond that distinction, these 
markers do not reliably distinguish between IPMNs and MCNs or malignancy.13,27 
Similarly, in the present study, no association was found between these MCN cyst-fluid 
values and the presence of malignancy.
Cross-sectional imaging findings perhaps can provide the greatest insight into the risk of 
malignancy through elucidation of MCN location and size and determination of the presence 
of mural nodules or pancreatic ductal dilation. Most MCNs have been reported in the 
pancreatic body and tail (89%–99%), with 84.2% in the present series.6,7,9,16,18–21 Although 
less common, MCN location in the pancreatic head has been associated with malignancy in 
other studies15,23 and in the present series. As in IPMNs, increased radiographic size also 
appears to be associated with malignancy in MCN. The mean size of all MCNs resected in 
this series was 5 cm, with increased size being associated with increased risk of malignancy, 
comparable to previous findings in the literature.6,15,18,20,21 In this study, no specific size 
was predictive of malignancy because adenocarcinoma or HGD was present even in small 
MCNs (<3 cm). In most of those cases, however, other risk factors, such as mural nodule or 
location in the pancreatic head and neck, were present. Such patterns have previously been 
described where tumors smaller than 3 to 5 cm without other concerning features (mural 
nodule or elevated CA19-9 level) were found to be benign.6,8,9,11,18–20 Across most 
studies,6,7,11,19–21 including the present one, mural nodules or solid components within an 
MCN have carried the highest risk of malignancy. In fact, in the small series of Le Baleur et 
al,18 a mural nodule on a computed tomogram was 100% sensitive and 98% specific for 
adenocarcinoma or HGD in MCNs. As such, presence of a mural nodule should be an 
indication for resection in appropriate surgical candidates. In IPMNs, duct dilation has been 
described as 1 risk factor for malignancy.13 Similarly, we found that, for MCNs, pancreatic 
ductal dilation represents an imaging finding that creates concern for malignancy.13
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The aforementioned risk factors (sex, location, radiographic size of the MCN, mural 
nodularity, and ductal dilation) could be considered in management strategies for patients 
with MCNs. As in IPMNs, perhaps not all patients with MCNs need to undergo resection 
but could be kept under radiographic surveillance. Furthermore, patients preoperatively 
identified to have low-risk MCNs may be candidates for parenchyma-sparing procedures 
rather than formal oncologic resections.28 This recommendation seems appropriate because, 
in the present series and the published literature,7,8,15,19,20 resection of an MCN that does 
not have an invasive component generally represents a curative procedure because events of 
recurrence after resection are extraordinarily rare. There are isolated reports of diffuse 
peritoneal recurrence after operative rupture of noninvasive MCNs and one instance of 
adenocarcinoma recurrence in a patient whose original pathologic findings were 
noninvasive, perhaps attributable to incomplete initial pathologic review.9,21 This finding 
thereby suggests resection of nonmalignant disease to be curative.
For patients with MCN-associated adenocarcinoma, the tumor behavior and biological 
features appear distinct from typical pancreatic ductal adenocarcinoma. The lymph node 
positivity rate in this series was only 34% and has been as low as 0% to 17% in the 
literature.8,19–21 The 3-year survival was 59% in the present series and has been reported at 
44% to 83% previously.6,21 Historically, typical pancreatic ductal adenocarcinoma is an 
aggressive disease process, being the fourth leading cause of cancer-related mortality in men 
and women in the United States.29 In typical pancreatic adenocarcinoma, the median 
survival is far less than 3 years, reported to be 17 to 24 months, whereas in the present series 
of MCN-associated carcinoma, the median survival extended beyond 3 years. This finding 
suggests that perhaps these are distinct malignant tumors with differing outcomes or that 
MCN-associated adenocarcinoma is typically resected earlier in the disease.30
To our knowledge, this study represents the first multi-institutional Western study of this 
latitude conducted in a population undergoing MCN resection after the publication of the 
WHO 2000 criteria that define MCNs by ovarian stroma.4,5 Thus, it is likely that during this 
timeframe in these academic institutions, MCNs were diagnosed using these pathologic 
criteria; however, given the scope and scale of the project across 8 different centers, 
pathologic re-review was not feasible to confirm the presence of ovarian stroma in all cases. 
Apart from the application of the WHO pathologic criteria, the ability to distinguish between 
IPMNs and MCNs with diagnostic certainty by imaging, preoperative laboratories, and 
cytologic testing is limited.13,27 As such, without strictly applying WHO pathologic criteria 
to define MCNs, some IPMNs can be misclassified as MCNs and thereby contaminate series 
of MCNs that have not strictly used WHO criteria.10,31 Therefore, the possibility exists that 
this series as well includes some patients with IPMNs; however, this contamination 
represents a clinical reality at the time point when physicians are determining treatment 
strategies for these patients. These WHO pathologic diagnostic criteria are only determined 
postoperatively on examination of surgical specimens. As such, these pathologic criteria are 
not available and thereby not applicable to the management decisions of these patients 
preoperatively. Thus, inclusion of patients who were diagnosed with MCNs not strictly 
defined by ovarian stroma is not only appropriate but also represents a clinical reality. In 
addition, in a study by Gil et al19 that examined MCNs diagnosed by WHO criteria 
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compared with MCNs less stringently diagnosed, no differences were found in the 
demographics, invasive cancer rates, or outcomes of these groups.
This study was limited by its retrospective design. All included patients underwent resection 
of MCNs, and thus the natural history of the disease in patients who did not undergo 
resection could not be studied. In addition, because this series only includes patients who 
underwent resection, there could be a potential selection bias for patients with more 
aggressive MCNs. Radiographic re-review was not conducted; thus, data were gathered 
solely from the radiologic reports from cross-sectional imaging and/or endoscopic 
ultrasonography, and missing data were treated as unknown data points. Patients were 
treated at 8 centers across the United States where diagnostic and treatment algorithms were 
not standardized. However, this diversity through potential differences among practice 
patterns across institutions also represents a strength because results can likely be 
generalized to the US population treated at academic institutions nationally.
Conclusions
Adenocarcinoma or HGD is present in 14.9% of resected pancreatic MCNs for which risks 
include male sex, pancreatic head and neck location, larger radiographic size of the MCN, 
solid component or mural nodule, and duct dilation. Mucinous cystic neoplasm-associated 
adenocarcinoma appears to have decreased nodal involvement and thus increased survival 
compared with typical pancreatic ductal adenocarcinoma. Indications for resection of MCNs 
should be revisited.
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Key Points
Question What are the preoperative risk factors for malignancy in pancreatic mucinous 
cystic neoplasms?
Findings In this multicenter retrospective analysis of 349 patients, independent 
preoperative risk factors for malignancy were male sex, pancreatic head and neck 
location, larger mucinous cystic neoplasm, solid component or mural nodule, and duct 
dilation.
Meaning Indications for resection of mucinous cystic neoplasms should be revisited.
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Figure 1. Recurrence-Free Survival of Patients With Mucinous Cystic Neoplasm-Associated 
Adenocarcinoma
The 3-year recurrence-free survival was 64%. Sixty months of follow-up was considered a 
reasonable length of time to illustrate; however, some patients continued follow-up beyond 
that point.
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Figure 2. Overall Survival of Patients With Mucinous Cystic Neoplasm-Associated 
Adenocarcinoma
The 3-year overall survival was 59%. Sixty months of follow-up was considered a 
reasonable length of time to illustrate; however, some patients continued follow-up beyond 
that point.
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Table 2
Binary Logistic Regression of Preoperative Risk Factors for Adenocarcinoma or High-Grade Dysplasia
Variable
OR (95% CI)
Univariate Analysis P Value Multivariable Analysis P Value
Male 4.61 (2.22–9.58) <.001 3.72 (1.21–11.44)   .02
BMI 0.96 (0.91–1.01)   .10 NA NA
Alcohol abuse 1.66 (0.59–4.69)   .34 NA NA
Smoking 1.35 (0.70–2.62)   .37 NA NA
Symptomatic 1.60 (0.83–3.09)   .16 NA NA
Radiographic size 1.12 (1.06–1.20) <.001 1.17 (1.08–1.27) <.001
Pancreatic head and neck lesion 4.45 (2.27–8.72) <.001 3.93 (1.43–10.81)   .01
Solid component or mural nodule 4.70 (2.36–9.36) <.001 4.54 (1.95–10.57) <.001
Duct dilation 5.35 (2.64–10.82) <.001 4.17 (1.63–10.64)   .003
Septations 0.77 (0.39–1.53)   .46 NA NA
Cyst fluid analysis
 Mucin presence 0.52 (0.18–1.48)   .22 NA NA
 CEA level 1.00 (1.00–1.00)   .63 NA NA
 Amylase level 1.00 (1.00–1.00)   .51 NA NA
Preoperative serum level
 CEA 1.00 (1.00–1.00)   .73 NA NA
 CA19-9 1.00 (1.00–1.00)   .18 NA NA
Abbreviations: BMI, body mass index; CEA, carcinoembryonic antigen; NA, not applicable; OR, odds ratio.
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Table 3
Mucinous Cystic Neoplasm-Associated Adenocarcinoma, Recurrence, and Survival in the 44 Patients With 
Adenocarcinomaa
Variable Finding
Lymph node positive 14 (34.1)
No. of positive lymph nodes, mean (SD)   0.8 (1.6)
Neoadjuvant
 Chemotherapy   5 (12.2)
 Radiotherapy   1 (2.4)
Adjuvant
 Chemotherapy 25 (61)
 Radiotherapy 15 (36.6)
Recurrence 11 (25.6)
Recurrence-free survival, % at 3 y 64
Death 12 (27.9)
Overall survival, % at 3 y 59
a
Data are presented as number (percentage) of patients unless otherwise indicated.
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